Mesoblast
MESO
13.94
+0.33
+2.42%
Mesoblast
US · MESO
#2849 by market cap
Listed 2015
13.94
+0.33
+2.42%
Live - 5344 symbols - heartbeat 523s ago
· 2026-10-08 07:49
Pre-market
13.70
-1.72%
After-hours
13.90
-0.29%
Overnight
13.48
-3.30%
- Market cap
- 1.81B
- P/E (TTM)i
- -31.68
- P/Bi
- 3.19
- EPSi
- -0.44
- Div yieldi
- 0.00%
- 52W posi
- 11%
Reader sentiment
Are you bullish or bearish on MESO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.50, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +599.21% YoY
Margins
- Gross margin
- 86.14%
- Operating margin
- -42.62%
- Net margin
- -47.82%
Key ratios & quality
- Enterprise valuei
- 1.89B
- Altman Z-Scorei
- 3.50
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.72M | 32.16M | 7.43M | 10.21M | 7.50M | 5.90M | 17.20M | 120.25M |
| Gross profit | -- | -- | -- | -- | 7.50M | 5.90M | 12.07M | 103.58M |
| Selling & admin expenses | 36.98M | 50.92M | 63.59M | 57.97M | 27.48M | 24.98M | 39.31M | 57.35M |
| Research & development | 59.82M | 56.19M | 53.01M | 32.82M | 52.82M | 39.72M | 34.81M | 97.51M |
| Operating profit | -80.41M | -75.41M | -107.60M | -81.11M | -69.29M | -56.22M | -62.44M | -51.25M |
| Pretax profit | -98.75M | -87.36M | -99.63M | -91.59M | -82.10M | -88.15M | -101.81M | -56.89M |
| Tax | -8.96M | -9.42M | -819.00K | -239.00K | -212.00K | -191.00K | 330.00K | 613.00K |
| Net profit | -89.80M | -77.94M | -98.81M | -91.35M | -81.89M | -87.96M | -102.14M | -57.50M |
| Basic EPS | -2 | -1 | -2 | -134 | -1 | -1 | -1 | 0 |
| Diluted EPS | -1.72 | -1.40 | -1.55 | -133.80 | -1.05 | -0.89 | -0.85 | -0.44 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 62.52M | 136.55M | 148.23M | 69.84M | 81.66M | 86.46M | 204.35M | 197.49M |
| Cash & ST investments | 50.01M | 128.92M | 136.43M | 60.03M | 70.92M | 62.56M | 161.16M | 47.39M |
| Inventory | -- | -- | -- | -- | -- | 0 | 22.25M | 28.11M |
| Total assets | 652.12M | 733.60M | 744.72M | 662.14M | 669.42M | 669.15M | 784.68M | 773.08M |
| Total current liabilities | 44.33M | 90.14M | 94.27M | 51.37M | 41.98M | 73.24M | 102.63M | 81.11M |
| Short-term debt | 14.01M | 35.97M | 55.97M | 8.20M | 10.01M | 16.49M | 56.84M | 13.63M |
| Long-term debt | 67.28M | 57.02M | 41.05M | 91.62M | 102.81M | 100.48M | 67.74M | 108.64M |
| Total liabilities | 171,063,000.00 | 184,276,000.00 | 163,320,000.00 | 165,098,000.00 | 167,577,000.00 | 188,798,000.00 | 187,241,000.00 | 204,674,000.00 |
| Total equity | 481.05M | 549.33M | 581.40M | 497.04M | 501.84M | 480.36M | 597.44M | 568.41M |
| Retained earnings | -469.99M | -548.76M | -647.57M | -738.92M | -820.81M | -908.76M | -1.01B | -1.07B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 204.35M | -- | 202.48M | -- | 197.49M |
| Cash & ST investments | -- | 161.16M | -- | 129.57M | -- | 47.39M |
| Inventory | -- | 22.25M | -- | 21.66M | -- | 28.11M |
| Total assets | -- | 784.68M | -- | 782.31M | -- | 773.08M |
| Total current liabilities | -- | 102.63M | -- | 128.07M | -- | 81.11M |
| Short-term debt | -- | 56.84M | -- | 69.12M | -- | 13.63M |
| Long-term debt | -- | 67.74M | -- | 60.13M | -- | 108.64M |
| Total liabilities | -- | 187,241,000.00 | -- | 207,623,000.00 | -- | 204,674,000.00 |
| Total equity | -- | 597.44M | -- | 574.68M | -- | 568.41M |
| Retained earnings | -- | -1.01B | -- | -1.05B | -- | -1.07B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -100.75M | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | 4.26M | -- | -- | -- | -- | -- |
| Free cash flow | -58.07M | -52.66M | -102.40M | -66.01M | -63.58M | -48.79M | -50.68M | -44.73M |
| Dividends paid | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 30.26M | 144.95M | 106.27M | 209.00K | 88.64M | 65.41M | 161.21M | 2.60M |
| Ending cash balance | 50.43M | 129.33M | 136.88M | 60.45M | 71.32M | 62.96M | 161.55M | 102.91M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -12.81M | -17.12M | -15.26M | -15.57M | -4.46M | -9.32M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 161.21M | 0 | 1.56M | 0 | 1.05M | 0 |
| Ending cash balance | 182.06M | 161.55M | 144.72M | 129.98M | 121.85M | 102.91M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -17.49 | -15.13 | -17.48 | -16.94 | -16.40 | -17.91 | -18.95 | -9.86 |
| ROA %i | -13.36 | -11.25 | -13.37 | -12.99 | -12.30 | -13.14 | -14.05 | -7.38 |
| ROIC %i | -13.51 | -10.78 | -12.43 | -11.54 | -10.36 | -11.36 | -13.50 | -6.52 |
| 5-year avg ROE %i | -11.63 | -10.96 | -14.29 | -14.73 | -16.69 | -16.77 | -17.54 | -16.01 |
| EBIT margin %i | -543.96 | -229.77 | -1,125.79 | -731.37 | -835.32 | -1,143.49 | -465.51 | -30.78 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.41 | 1.51 | 1.57 | 1.36 | 1.95 | 1.18 | 1.99 | 2.43 |
| Quick ratioi | 1.21 | 1.44 | 1.50 | 1.25 | 1.86 | 1.14 | 1.72 | 1.30 |
| Debt / assetsi | 12.47 | 13.54 | 14.17 | 16.15 | 17.40 | 17.77 | 16.33 | 16.47 |
| LT debt / equityi | 13.99 | 11.53 | 8.52 | 19.86 | 21.22 | 21.32 | 11.94 | 20.00 |
| Interest coveragei | -7.44 | -4.94 | -5.25 | -4.42 | -3.22 | -3.27 | -3.68 | -1.86 |
| Revenue CAGR (3Y) %i | -26.12 | 153.35 | -24.06 | -15.16 | -38.09 | -7.40 | 18.98 | 152.15 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -18.95 | -- | -18.22 | -- | -9.86 |
| ROA %i | -- | -14.05 | -- | -13.15 | -- | -7.38 |
| ROIC %i | -- | -13.50 | -- | -12.76 | -- | -6.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -465.51 | -- | -109.29 | -- | -30.78 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 1.99 | -- | 1.58 | -- | 2.43 |
| Quick ratioi | -- | 1.72 | -- | 1.35 | -- | 1.30 |
| Debt / assetsi | -- | 16.33 | -- | 17.28 | -- | 16.47 |
| LT debt / equityi | -- | 11.94 | -- | 11.49 | -- | 20.00 |
| Interest coveragei | -- | -3.68 | -- | -3.20 | -- | -1.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development of adult stem cell technology platform for commercialization100.00%
Region
Australia100.00%
Quote time 2026-10-08 07:49:29 · For reference only, not investment advice and not tailored to your situation.